NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

Search

Johnson and Johnson

Fechado

SetorSaúde

168.27 -0.78

Visão Geral

Variação de preço das ações

24h

Atual

Mín

167.42

Máximo

169.81

Indicadores-chave

By Trading Economics

Rendimento

7.6B

11B

Vendas

1.9B

24B

P/E

Médio do Setor

17.579

38.156

EPS

2.77

Rendimento de Dividendos

3.07

Margem de lucro

50.24

Funcionários

138,100

EBITDA

-9.1B

6.5B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+4% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.07%

2.50%

Próximos Ganhos

14 de out. de 2025

Próxima data de dividendos

9 de set. de 2025

Próxima data de ex-dividendo

26 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

18B

395B

Abertura anterior

169.05

Fecho anterior

168.27

Sentimento de Notícias

By Acuity

33%

67%

95 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Johnson and Johnson Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de jul. de 2025, 16:47 UTC

Ganhos

J&J Raises Full-Year Outlook After Beating 2Q Expectations -- Update

16 de jul. de 2025, 18:08 UTC

Conversa de Mercado
Ganhos

J&J's Orthopedic Decline Likely Hinges on Company-Specific Challenges -- Market Talk

16 de jul. de 2025, 17:27 UTC

Conversa de Mercado
Ganhos

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

16 de jul. de 2025, 17:17 UTC

Conversa de Mercado
Ganhos

J&J Sees Growth Across Portfolio Offsetting Loss of Stelara -- Market Talk

16 de jul. de 2025, 16:34 UTC

Conversa de Mercado
Ganhos

J&J Sees Lower Tariff Risk for the Year -- Market Talk

16 de jul. de 2025, 13:27 UTC

Ganhos

Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants. -- Barrons.com

16 de jul. de 2025, 10:32 UTC

Ganhos

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 de jul. de 2025, 10:22 UTC

Ganhos

Correct: Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.63-$10.73 Vs Prior Outlook $10.50-$10.70 >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Raises 2025 View To Sales $93.2B-$93.6B Vs Prior Outlook $91B-$91.8B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Raises 2025 View To Adj EPS $10.80-Adj EPS $10.90 Vs Prior Outlook $10.50-$10.70 >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.5%-5% Vs Prior Range 3.3%-4.3% >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Now Sees 2025 Operational Sales of $92.7B-$93.1B Vs Prior Outlook $91.6B-$92.4B>JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: Our Portfolio and Pipeline Position Us for Elevated Growth in Second Half of Year >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.2%-3.7% Vs Prior Outlook 2%-3% >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: 2Q MedTech Business Delivered Operational Sales Growth of 6.1%, Driven Primarily by Strength in Electrophysiology Products and Abiomed, Wound Closure Pdts and Improved Performance in Surgical Vision >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q Worldwide MedTech Sales $8.54B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Rybrevant, Lazcluze, Tremfya and Spravato >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Grew 3.8% With 13 Brands Growing Double Digits >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q International Sales $23.74B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q U.S. Sales $13.54B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q Sales $23.74B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q EPS $2.29 >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q Adj EPS $2.77 >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q Orthopaedics Sales $2.3B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 de jul. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

Comparação entre Pares

Variação de preço

Johnson and Johnson Previsão

Preço-alvo

By TipRanks

4% parte superior

Previsão para 12 meses

Média 176.35 USD  4%

Máximo 190 USD

Mínimo 160 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Johnson and Johnson - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

9

Comprar

10

Manter

0

Vender

Pontuação Técnica

By Trading Central

154.93 / 155.895Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

95 / 375 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.